Corbus Pharmaceuticals Holdings Inc stock is traded at $3.07, with a volume of 684,165. It is up +7.34% in the last 24 hours and down -46.89% over the past month. Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Previous Close:
$2.86
Open:
$2.93
24h Volume:
684,165
Relative Volume:
0.45
Market Cap:
$59.38M
Revenue:
$1.54M
Net Income/Loss:
-$84.53M
P/E Ratio:
-
EPS:
-$5.81
Net Cash Flow:
-$73.65M
1W Performance:
-27.25%
1M Performance:
-46.89%
6M Performance:
-71.89%
1Y Performance:
-70.59%
1-Day Range:
$2.91$3.13
1-Week Range:
$2.81$4.23
52-Week Range:
$2.81$12.88
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
Name
Corbus Pharmaceuticals Holdings IncSector
HealthcareIndustry
BiotechnologyPhone
617-963-0103Address
500 RIVER RIDGE DRIVE, NORWOOD, MA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS